Meridian v. Cascade: Bombay HC Restrains ‘NACOMIST’ Under Consent Terms

What Sparked the Dispute Between Meridian Enterprises Pvt Ltd and Cascade India Pharmaceuticals?

Looking to understand Trademark Law better? Read our complete Trademark Law Guide.

In Meridian Enterprises Pvt Ltd Vs Cascade India Pharmaceuticals, the Bombay High Court on 10th September 2026, disposed of a commercial intellectual property suit after the parties reached a settlement through formal consent terms. The dispute, registered under IA/6540/2025, primarily concerned allegations of trademark infringement and potential passing off within the pharmaceutical sector, where brand identity and market exclusivity are critical to the protection of commercial interests under the Trade Marks Act, 1999.

Presiding over the dispute, Justice Madhav J. Jamdar recorded the consent terms submitted jointly by Meridian Enterprises Private Limited and Cascade India Pharmaceuticals. The plaintiff, Meridian Enterprises, had initiated the action to protect its registered trademark NASOMIST, registered under trade mark registration No. 597366 in respect of pharmaceutical and medicinal preparations.

The defendants included Cascade India Pharmaceuticals (a partnership firm) alongside its two partners, Vinay Kumar Jain and Vishal Bindra. The defendants entered an appearance through counsel, confirmed their signatures on the settlement deed, and agreed to submit to a decree on admission in terms of the principal prayers in the plaint. In view of the disposal of the main suit, the court also disposed of the pending interim application.

Technical / Market Context & Framed Legal Issues

Pharmaceutical trademarks operate under stringent judicial scrutiny in India. In Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73, the Supreme Court established that confusing similarity between medicinal brands creates risks to public health and patient safety. Even slight phonetic or visual proximity can lead to dispensing errors at the pharmacy counter.

Here, Meridian held statutory exclusivity over NASOMIST for medicinal and pharmaceutical preparations. The defendants adopted NACOMIST for allied pharmaceutical formulations. The substitution of the single consonant ‘S’ with ‘C’ created immediate phonetic, structural, and visual resemblance. Because both parties marketed medicinal preparations, the plaintiff sought injunctive relief under Section 29 of the Trade Marks Act, 1999 for registered trademark infringement and common law passing off. The legal issue before the Bombay High Court was whether the negotiated consent terms satisfied the statutory requirements of Order XXIII Rule 3 of the Code of Civil Procedure, 1908 and whether the court should adopt the private compromise as a binding judicial decree.

Substantive Analysis of Consent Terms and Undertakings

Under Order XXIII Rule 3 of the Code of Civil Procedure, 1908, a court must verify that an agreement or compromise is in writing, signed by the parties, and lawful before passing a decree in accordance with its terms. In this suit, the authorized representatives executed the document before the court. Paresh Patel, Assistant Manager (Distribution), signed on behalf of Meridian Enterprises. Partners Vinay Kumar Jain and Vishal Bindra signed on behalf of Cascade India Pharmaceuticals, while advocates from both sides formally identified the signatures.

Under clause 2 of the consent terms, the defendants submitted to a decree on admission in terms of prayers (a) and (b) of the plaint. The perpetual injunction restrains Cascade India, its partners, servants, agents, and distributors from manufacturing, selling, marketing, exporting, or promoting goods under the impugned mark NACOMIST. The injunction covers any identical or deceptively similar mark that infringes Meridian’s registered mark NASOMIST or causes passing off.

Under clause 3, the defendants undertook never to use any mark deceptively similar to the plaintiff’s trademarks in the future. Justice Jamdar explicitly ordered that the court accepted these statements as undertakings given to the court. By elevating these covenants to court undertakings, the order equips the plaintiff with the power to initiate contempt proceedings under the Contempt of Courts Act, 1971 if the defendants breach their commitments. Clause 7 reinforces this protection by providing that any breach obligates the defendants to pay the full damages claimed in the original plaint.

Inventory Exhaustion and Registry Application Withdrawal

A critical vulnerability in pharmaceutical settlements is the persistence of existing packaging in distribution chains or pending applications at the Trade Marks Registry. The consent terms in this suit directly closed both avenues.

Under clause 4, Cascade India confirmed that it holds no stock or packaging material bearing the mark NACOMIST. The defendants placed on record their final manufacturing run of Batch No. 4403, manufactured in September 2024 with an expiry date of August 2026. Specifying the exact batch details establishes a clear baseline for market monitoring and removes ambiguity regarding post-settlement commercial activity.

Under the subsequent sub-clause, the defendants confirmed that they formally withdrew Trade Mark Application No. 5440462 for the mark NACOMIST through a withdrawal letter dated 18 June 2025 addressed to the Registrar of Trade Marks. The defendants also undertook not to file any future trademark or copyright applications containing the word NACOMIST. In exchange, under clause 9, Meridian gave up its remaining financial claims and prayers in the suit.

Also Read: Calcutta HC Returns ITC Plaint for Skipping Section 12A Mediation

Decision and Judicial Significance

Justice Jamdar accepted the consent terms, decreed Commercial IP Suit No. 600 of 2025 in terms of the compromise, and disposed of Interim Application No. 6540 of 2025. The court also permitted a refund of the court fees in accordance with the applicable High Court rules.

This order demonstrates how commercial courts facilitate the swift, final resolution of intellectual property disputes when parties negotiate precise terms. Settling through a formal consent decree provides three direct benefits. First, it eliminates the delay, expense, and uncertainty of trial while securing permanent injunctive protection. Second, it transforms contract promises into enforceable judicial undertakings backed by contempt sanctions. Third, it allows the plaintiff to recoup court fees under statutory refund rules, lowering the net financial cost of brand enforcement.

Case Details:

Counsel for Parties: Mr. Kaivalya Shetye i/b Mr. Mahesh Mahadgut for the Plaintiff, and Mr. Akash P. Shah for the Defendants

Matter: Meridian Enterprises Private Limited v. Cascade India Pharmaceuticals & Ors.

Court / Authority: High Court of Judicature at Bombay (Commercial Division)

Presiding Officer / Bench: Hon’ble Mr. Justice Madhav J. Jamdar